Lunda Company CLS are active in image-guided laser ablation treatment for soft tissue, such as cancer tumors, and develop their own products for such treatment. CLS has also developed the method Immune-stimulating interstitial thermotherapy (imILT) for the treatment of cancer tumors and it is a type of cooled fiber technology that can be used in imILT treatment that the patent covers.
Image-guided laser treatment
imILT is a heat treatment that targets the outer surface of the tumor, i.e. where the tumor grows. The method involves first heating the tumor for a period and then following the active treatment period. In addition to killing the cancer tumor, imILT also has the potential to stimulate the immune system to affect any metastases in the body.
The heat is conducted into the tumor through an optical laser fiber that is inserted into the tumor and the newly registered Japanese patent protects a fiber technology for cooled fiber that CLS previously used. Over time, CLS has developed a technology for a non-cooled fiber, which is the one that is currently in the company's product portfolio, but it is strategically important to cover other technologies and make it difficult for competitors to develop a similar product.
The patent protects CLS's position
Last year, CLS obtained a corresponding patent in Europe and now we can see strengthened patent protection in the international market through the Japanese patent. This was underlined by Stephan Dymling, CTO at CLS, in a press release:
"Like the corresponding patent in Europe, the purpose of a patent in Japan is to close the possibility for competitors to develop a cooled fiber for our imILT protocol. CLS uncooled fiber has a unique position and we want to make sure to maintain it." – Stephan Dymling, CTO, CLS
The content of BioStock's news and analysis is independent, but BioStock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.